Linden LLC

Linden Finances IVX Health’s Acquisition of Precision Healthcare

October 15, 2020 | For Immediate Release

Chicago, IL (October 15, 2020) – Linden Capital Partners (“Linden”), a Chicago-based private equity firm focused exclusively on the healthcare sector, completed its preferred equity investment in IVX Health (“IVX” or the “Company”), a national provider of infusion and injection therapy for patients with complex chronic conditions such as multiple sclerosis, Crohn’s disease, and rheumatoid arthritis. Linden joins IVX’s other institutional investors, McKesson Ventures, Health Velocity Capital, and Nueterra Capital. Linden’s investment will fund the Company’s acquisition of Precision Healthcare (“Precision”), formerly a subsidiary of BAI Healthcare Services, Inc. Based in Nashville, Tenn., Precision operates 12 infusion centers across Tennessee and northern Arkansas.

“In addition to putting patients first, IVX Health has a history of expansion and consistently delivering high quality care. As the company has scaled, it has also successfully integrated teams, aligned operating processes, and replicated its exceptional culture across a network of sites,” said Scott Gallin, Linden Partner. “We are excited to partner with IVX and fully support its vision to become the national destination of choice for infusion therapy for both patients and referring specialist physicians.”

The acquisition of Precision accelerates IVX’s national growth strategy, improving access for patients by adding to its already expansive footprint. With the completion of the acquisition, IVX is now one of the largest providers of infusion and injection therapy in the nation, operating over 35 ambulatory infusion centers across the United States. IVX expects it will continue to complement its de novo strategy with additional acquisitions.

“The Precision team has built an amazing company that shares the same passion and commitment as IVX for caring for those with complex chronic conditions,” said Doug Ghertner, CEO of IVX. “Together we have the opportunity to meaningfully impact the lives of even more patients by investing in Precision’s existing footprint in ways that expand patient access and enhance the overall patient experience.” Ghertner added, “We are very excited about Linden’s support for IVX, which further validates our growth strategy in the ambulatory infusion sector. Linden’s exclusive focus on the healthcare sector was evident throughout the transaction process, and we are excited to have them as a valuable partner moving forward.”

Precision’s corporate operations will rebrand as IVX immediately, with plans to rebrand designated Precision sites over the next year. For more information regarding this acquisition, please visit the IVX Health website.

About IVX Health
IVX Health is a national provider of infusion and injection therapy for those with complex chronic conditions such as rheumatoid arthritis, Crohn’s disease, multiple sclerosis and other conditions.
IVX Health’s national footprint of outpatient infusion centers is conveniently located in the communities where patients live and work. IVX Health’s experience-first model includes amenities such as flexible appointment scheduling with evening and weekend availability, guaranteed private suites, high-speed Wi-Fi, flat screen TVs with streaming TV and movies, and comfortable recliners with room for guests.

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested more than $2 billion in healthcare companies and has raised nearly $3 billion of commitments, augmented by capital provided by the firm’s limited partners for larger transactions. For more information, please visit